Asthma disparities by race and ethnicity in the U.S. may be influenced by differences in asthma drug response: African American and Puerto Rican children have lower drug response to bronchodilators, the most commonly used asthma rescue therapy. In this talk, we will present results from whole genome sequencing association analyses for bronchodilator response (BDR) among 6385 minority children from the Asthma Translational Genomics Collaboration (ATGC) that is part of the NHLBI’s TOPMed program. Genome-wide association analyses for BDR were conducted with TOPMed Freeze 8 data for each cohort and racial/ethnic group using linear mixed models, while adjusting for sex, age, BMI and four principal components. Racial/ethnic-specific and overall meta-analyses were performed using METASOFT under a fixed-effects model. Among common variants (MAF>0.01), the top association in 4562 African American children was nearest IZUMO3, in 1154 Puerto Rican children was nearest DNAH5, and in 669 Mexican children was nearest ZNF311. Across all racial-ethnic groups, the top variant was nearest SFXN4. We previously developed the app Reducing Associations by Linking Genes And omics Results (REALGAR) that provides insights helpful for prioritizing and designing functional validation studies for genetic associations using publicly available omics data. Using REALGAR, we found that 1) SFXN4 had decreased expression (q=3.8e-4) in whole blood of 318 people with severe asthma versus 87 healthy controls (GSE69683), 2) ZNF311 had increased expression (q=5.3e-7) and 3) DNAH5 and decreased expression (q=5.5e-25) in airway smooth muscle exposed to 100nM budesonide for 18hr (SRP098649). Thus, cell-specific omics suggests potential disease mechanisms of BDR associations and are useful to prioritize associated genes and facilitate the design of validation experiments.